Navigation Links
Reportlinker Adds Future of Red Biotechnology in China
Date:4/26/2010

NEW YORK, April 26 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Future of Red Biotechnology in China

http://www.reportlinker.com/p0189383/Future-of-Red-Biotechnology-in-China.html

Red biotechnology (RB) refers to the biotechnology applied in pharmaceutical production and it has become the most important part in biotechnology industry. About 60% of achievements in biotechnology in the world are applied in production of bio-pharmaceuticals. At present, RB products mainly include gene recombinant drugs, blood products, vaccines, diagnostic reagents, etc. What is the current production situation of different RB products in China?

Driven by its substantial environmental or economic benefits, China's RB industry has witnessed fast development and has played an increasingly important role in Chinese economic growth. However, the overall development of China's RB industry remains in growth stage, and still has an enormous gap compared with developed countries. What is the future trend of Chinese RB industry development? What are the relevant supporting policies on Chinese RB industry? What have been the popular cutting-edge technologies in China in recent years? Where are the investment opportunities and what is the investment mode in China?

What is covered in this report?

- Overview of China's red biotechnology;

- Detailed analysis of each sub-categories of red biotechnologies in China: gene recombinant drugs, blood products, vaccines, diagnostic reagent, etc., in terms of market data, major players, technical suppliers, technologies or R&D situations;

- Future prospects of each category of red biotechnologies, with key influencing factors and commercial opportunities

- Profiles of major players and research institutes

- Related policies and regulations

What benefits will you get?

- Gain a clear understanding about the industry landscape and latest developments in R&D, production, technology advancement and future trends in China's red biotechnology;

- Keep informed of the precise development situation of key RB products with basic data and latest info;

- Gain reasonable and constructive suggestions on market opportunities in China's RB fields;

- Figure out, current trend and future growth prospect of red biotechnology in China;

- Know more about how innovative players and research groups are carrying out innovation, collaboration and achieving commercial success in China.

Companies Mentioned

Shenyang Sunshine Pharmaceutical Co., Ltd., Hualan Biological Engineering Inc., Zhejiang Tianyuan Bio-Pharmaceutical Co., Ltd., Beijing Tiantan Biological Products Co., Ltd., Shanghai Kehua Bio-engineering Co., Ltd.,

Executive summary

Methodology & sources

I Overview of red biotechnology in China

Introduction to red biotechnology

Role of red biotechnology in medicine industry

Overview of red biotechnology development

II Development environment of red biotechnology in China

II-1 Macro economic environment

II-2 Policy environment

II-3 Medicine industry development

II-4 Venture capital

III Market segments of red biotechnology industry in China

III-1 Gene recombinant drugs

III-1.1 Erythropoietin(EPO)

III-1.2 Insulin

III-1.3 G-CSF

III-1.4 Rh-GH

III-1.5 Interferon

III-1.6 Anti-tumor monoclonal antibody

III-2 Blood products

III-3 Human vaccines

III-4 Diagnostic reagent

III-4.1 Diagnostic reagent history in China

III-4.2 Current production situation in China

III-4.3 Producers information of Chinese diagnostic reagent

III-4.3.1 Biochemical diagnostic reagent

III-4.3.2 Immunodiagnostic reagent

III-4.3.3 Molecular diagnostic reagent

III-4.3.3.1 PCR reagent

III-4.3.3.2 Biochips

III-4.4 Forecast

III-5 Other red biotechnology based drugs

III-5.1 Antibiotic

III-5.1.1 Current antibiotic production in China

III-5.1.2 Penicillin production technology

III-5.1.3 Waste treatment technology

III-6 Forecast on supply & demand to the next 5~10 years

III-6.1 Forecast on gene recombinant market during 2010~2020

III-6.1.1 Supply of gene recombinant drugs during 2000~2020

III-6.1.2 Demand for gene recombinant drugs during 2009~2020

III-6.1.3 Difference between demand and supply during 2009~2020

III-6.2 Forecast on blood product market during 2010~2020

III-6.2.1 Supply of blood products during 2005~2020

III-6.2.2 Demand for blood products during 2009~2020

III-6.2.3 Difference between demand and supply during 2009~2020

III-6.3 Forecast on human vaccine market during 2010~2020

III-6.3.1 Supply of human vaccines during 2005~2020

III-6.3.2 Demand for human vaccines during 2009~2020

III-6.3.3 Difference between demand and supply during 2009~2020

III-6.4 Forecast on diagnostic reagent market during 2010~2020

III-6.4.1 Supply of diagnostic reagents during 2005~2020

III-6.4.2 Demand for diagnostic reagents during 2009~2020

III-6.4.3 Difference between demand and supply during 2009~2020

IV Cutting edge technology development in China

IV-1 Stem cell treatment

IV-2 Monoclonal antibody

IV-3 Diagnostic reagent

IV-4 Vaccine

V Geographical distribution of China's red biotechnology industry

V-1 Regional distribution

V-2 Introduction to RB industrial clusters

V-3 Overview of major RB industrial bases

V-3.1 Changsha National Biomedical Industrial Base

V-3.2 Zhangjiang National Biomedical Industrial Base

V-3.3 Zhongguancun National Biomedical Industrial Base

V-3.4 Shenzhen National Biological Industry Base

V-3.5 Changchun National Biological Industry Base

V-3.6 Guangzhou National Biological Industry Base

V-3.7 Shijiazhuang National Biological Industry Base

V-4 Forecast on national biological industry base in the next 5~10 years

VI Analysis of main Chinese companies in red biotechnology

VI-1 Choice of main Chinese companies in red biotechnology industry

VI-2 Analysis on main Chinese companies in red biotechnology industry

VI-2.1 Company engaged in biotech drugs

- Shanghai FOSUN Pharmaceutical (GROUP) Co., Ltd.

VI-2.2 Companies engaged in blood products

- Shanghai RAAS Blood Products Co., Ltd.

- Hualan Biological Engineering,Inc.

VI-2.3 Company engaged in vaccine

- Beijing Tiantan Biological Products Co.,Ltd.

VI-2.4 Company engaged in bio-engineering drugs

- Beijing SL Pharmaceutical Co., Ltd.

VI-2.5 Company engaged in antibiotics

- Shangdong Lukang Pharmaceutical Co.,Ltd.

VI-2.6 Company engaged in diagnostic reagents

- Shanghai Kehua Bio-Engineering Co.,Ltd.

VII Main foreign involvement in China's red biotechnology

VII-1 Foreign companies in China

VII-1.1 GlaxoSmithKline (China) Co., Ltd.

VII-1.2 Pfizer (China) Co., Ltd.

VII-1.3 Novartis (China) Co., Ltd.

VII-1.4 Sanofi Pasteur (China) Co., Ltd.

VII-2 Comparison of foreign companies and Chinese companies

VII-3 Forecast of foreign involvement in China in next 5~10 years

VII-3.1 Forecast on Novartis expansion in China

VII-3.2 Forecast on GSK expansion in China

VII-3.3 Forecast on Sanofi-aventis expansion in China

VIII Analysis of investment in the next 5 years

VIII-1 Investment opportunities in biopharmaceutical industry

VIII-1.1 Solid foundation of bio-pharmaceutical investment

VIII-1.2 Investment hotspots in China

VIII-2 Risk analysis of the investment in China's red biotechnology

VIII-2.1 Risk from international environment

VIII-2.2 Risk from domestic environment

VIII-2.3 Estimation of bio-pharmaceutical investment risk in the next 5 years

IX Profiles of key players in China

IX-1 Companies

IX-1.1 Gene recombinant drugs

IX-1.2 Blood products

IX-1.3 Vaccine

IX-1.4 Diagnostic reagent

IX-2 Research institutes

LIST OF TABLES

Table II-1.1 Annual benchmark lending rate of RMB

Table II-2 Relevant policies on bio-pharmaceutical industry in China, 2006-2009

Table II-3.1 Medicine industry output value in China, 2004-2008, billion USD

Table III-1.1.1 Market share of major EPO manufacturers, 2009

Table III-1.2.1 Three generations of insulin

Table III-1.2.2 Main rh-insulin manufacturers in China, 2009

Table III-1.3.1 Output of some G-CSF manufacturers, 2008

Table III-1.4.1 Market share of main rh-GH manufacturers in China, 2006-2008

Table III-1.5.1 Top four interferon manufacturers in China, 2009

Table III-1.5.2 Market share of main interferon manufacturers in China, 2006-2008

Table III-1.6.1 List of imported anti-tumor monoclonal antibody drugs

TableIII-1.6.2 List of domestic anti-tumor monoclonal antibody drugs

Table III-2.1 Some major human albumin manufacturers in China, 2010

Table III-2.2 Human albumin output of major manufacturers in China, 2008-2009

Table III-2.3 Human immunoglobulin for intravenous injection output of major manufacturers, 2009

Table III-3.1 Vaccines belonging to National Immunization Program, 2010

Table III-3.2 Average import and export prices of human vaccines, 2006-2009

Table III-3.3 Production situation of H1N1 Influenza A Vaccine in China, 2010 (Unit: thousand doses)

Table III-3.4 Monthly lot release volume of top 4 H1N1 Influenza A vaccine in China, Sep-Dec. 2009 (Unit: thousand doses)

Table III-3.5 All Inactivated Split Influenza vaccine lot release in China, 2009

Table III-3.6 Situation of domestic HBV lot release, 2007-2009 (unit: thousand doses)

Table III-3.7 Major manufacturers' HBV lot release situation, 2009 (unit: thousand doses)

Table III-3.8 Lot release volume of some major human vaccines, 2007-2009

Table III-4.1 Comparison of three main diagnostic reagents

Table III-4.3.1 Major diagnostic reagent producers in China, 2008

Table III-4.3.1.1 Top 3 producers of biochemical diagnostic reagents in China, 2008

Table III-4.3.2.1 Some producers of immunodiagnostic reagent in China, 2008

Table III-4.3.3.1.1 Major PCR reagent producers in China, 2008

Table III-4.3.3.2.1 Some biochips producers in China, 2009

Table III-6.1.1.1 Supply of four gene recombinant drugs in China, 2000-2020

Table III-6.1.1.2 Supply of gene recombinant drugs in China, 2009-2020

Table III-6.1.2.1 Demand for gene recombinant drugs in China, 2009-2020

Table III-6.1.3.1 Demand & supply gap of gene recombinant drugs in China, 2009-2020

Table III-6.2.1.1 Supply of blood products in China, 2005-2020

Table III-6.2.2.1 Demand for blood products in China, 2009-2020

Table III-6.2.3.1 Demand & supply gap of blood products in China, 2009-2020

Table III-6.3.1.1 Supply of human vaccines in China, 2005-2020

Table III-6.3.2.1 Demand for human vaccines in China, 2009-2020

Table III-6.3.3.1 Demand & supply gap of human vaccines in China, 2009-2020

Table III-6.4.1.1 Supply of diagnostic reagents in China, 2005-2020

Table III-6.4.2.1 Demand for diagnostic reagents in China, 2009-2020

Table III-6.4.3.1 Demand & supply gap of diagnostic agents in China, 2009-2020

Table IV-3.1 Info about HIV diagnostic kit of different generation

Table V-1.1 Top 10 RB industrial regions by output value in China, 2008

Table V-1.2 Top 10 RB industry regions by profit, 2008

Table V-2.1 Seven National Biomedical Industrial Bases

Table V-3.1.1 Eight investment sectors of this Base

Table V-3.1.2.1 Incentives provided by the Base

Table V-3.1.2.2 High-quality research centers in the Base

Table V-3.2.2.1 Professional organizations

Table V-3.2.2.2 Venture Service Centre

Table V-3.3.2.1 Platform of Bio-technology

Table V-3.3.2.2 Animal base

Table V-3.3.2.3 R&D support

Table V-3.3.2.4 Main equipments and instruments in second-stage test workshop

Table V-3.5.1 Research centers

Table VI-1.1 Major listed bio-pharmaceutical companies and their achievements

Table VI-2.1.1 Employee structure in Shanghai FOSUN

Table VI-2.1.2 Business performance of Shanghai FOSUN by field and product, H1 2009

Table VI-2.1.3 Business performance of Shanghai FOSUN in different regions, H1 2009

Table VI-2.1.4 Financial indicators of Shanghai FOSUN, 2007- 2009

Table VI-2.2.1 Main products of Shanghai RAAS

Table VI-2.2.2 Employee structure of Shanghai RAAS

Table VI-2.2.3 Business performance of Shanghai RAAS by field and product, H1 2009

Table VI-2.2.4 Business performance of Shanghai RAAS in different regions, H1 2009

Table VI-2.2.5 Financial indicators of Shanghai RAAS, 2007 - 2009

Table VI-2.2.6 Employee structure of Hualan Biological

Table VI-2.2.7 Business performance of Hualan Biological by field and product, H1 2009

Table VI-2.2.8 Business performance of Hualan Biological in different regions, H1 2009

Table VI-2.2.9 Financial indicators of Hualan Biological, 2007- 2009

Table VI-2.3.1 Employee structure of Tiantan Biological

Table VI-2.3.2 Business performance of Tiantan Biological by product, H1 2009

Table VI-2.3.3 Business performance of Tiantan Biological, H1 2009

Table VI-2.3.4 Financial indicators of Tiantan Biological, 2007- 2009

Table VI-2.4.1 Employee structure of Beijing SL

Table VI-2.4.2 Business performance of Beijing SL by field and product, H1 2009

Table VI-2.4.3 Business performance of Beijing SL in different regions, H1 2009

Table VI-2.4.4 Financial indicators of Beijing SL, 2007-2009

Table VI-2.5.1 Employee structure of Shandong Lukang

Table VI-2.5.2 Business performance of Shandong Lukang by product, H1 2009

Table VI-2.5.3 Business performance of Shandong Lukang in different regions, H1 2009

Table VI-2.5.4 Financial indicators of Shandong Lukang, 2007- 2009

Table VI-2.6.1 R&D Events reflecting research capability of Shanghai Kehua, 2005~2009

Table VI-2.6.2 Four major diagnostic reagents of Shanghai Kehua

Table VI-2.6.3 Employee structure of Shanghai Kehua

Table VI-2.6.4 Business performance of Shanghai Kehua by field and product, H1 2009

Table VI-2.6.5 Business performance of Shanghai Kehua in different regions, H1 2009

Table VI-2.6.6 Financial indicators of Shanghai Kehua, 2007-2009

Table VII-1.1.2.1 Prescription medicines introduced by GSK China into China

Table VII-1.1.2.2 Vaccines introduced by GSK China into China

Table VII-1.1.2.3 OTC medicines marketed by GSK China in China

Table VII-1.1.2.4 Healthcare products of GSK China in China

Table VII-1.4.2.1 Bacterial diseases and viral diseases

Table VII-2.1 Financial performance comparison of Chinese and overseas biopharmaceutical companies, 2008-2009

Table VII-3.1.1 Industry sales and growth of Novartis, 2010~2015

Table VII-3.2.1 Industry sales and growth of GSK, 2009

Table VII-3.3.1 Sanofi-aventis industry sales and growth in 2008 and 2009

Table VIII-1.1.1 Main bio-industry policies

Table VIII-2.2.1 regulatory policies and main impacts

Table VIII-2.2.2 Important regulatory policies about blood product industry

Table VIII-2.2.3 Average R&D expenses of different era in the world

Table VIII-2.2.4 Domestic higher education graduates of biochemical pharmaceutical major

Table VIII-2.2.5 Employees of bio-chemical and bio-pharmaceutical enterprises

Table VIII-2.3.1 Estimated values of investment risks and EVBIR

LIST OF FIGURES

Figure I.1 Output value of bio-pharmaceuticals in China, 2004-2009

Figure I.2 Proportion of bio-pharmaceuticals in China's medicine industry, 2009

Figure I.3 RB industrial output value changes in the proportion of China's GDP, 2004-2009

Figure II-1.1 China's GDP growth, 2004-2009

Figure II-2.1 Per capita disposable income of urban residents in China, 2004-2009

Figure II-3.1 Medicine industry output value in China, 2004-Nov.2009

Figure II-4 Procedure of venture capital in bio-pharmaceutical industry

Figure III-1.1.1 EPO market value in China, 1999-2009

Figure III-1.1.2 Forecast on EPO market value, 2010-2014

Figure III-1.2.1 Global l insulin market value structure, 2009

Figure III-1.2.2 Insulin market value structure in China, 2009

Figure III-1.2.3 Output of rh-insulin in China, 2007-2009

Figure III-1.2.4 Number of global diabetes patients, 1985-2007

Figure III-1.2.5 Number of diabetes patients in China, 1978-2007

Figure III-1.2.6 Market value of insulin in China, 2005-2009

Figure III-1.2.7 Insulin import and export under HS code 29371200 in China, 2006-2009

Figure III-1.2.8 Insulin import and export under HS code 30043100 in China, 2006-2009

Figure III-1.2.9 Forecast on insulin market value, 2010-2014

Figure III-1.3.1 Procurement value of G-CSF of all Chinese hospitals, 2004-2008

Figure III-1.4.1 Output of rh-GH in China, 2006-2009

Figure III-1.4.1 Market value of rh-GH in China, 2004-2009

Figure III-1.4.3 Forecast on rh-GH output, 2010-2014

Figure III-1.4.4 Forecast on rh-GH market value, 2010-2014

Figure III-1.6.1 Global market value of anti-tumor monoclonal antibody, 2000-2009

Figure III-1.6.2 Proportion of bio-pharmaceuticals market value in drug market, 2001-2007

Figure III-1.6.3 Proportion of anti-tumor monoclonal antibody market value in bio-pharmaceuticals market, 2007

Figure III-1.6.4 Rituximab market value in China, 2003-2008

Figure III-1.6.5 Trastuzumab market value in China, 2003-2008

Figure III-2.1 Geographical distribution of blood product manufacturers in China, 2009

Figure III-2.2 Output of human albumin in China, 2004-2009

Figure III-2.3 Average yield of human albumin in China, 2004-2008

Figure III-2.4 Number Changes in active human albumin producers, 2004-2009

Figure III-2.5 Human albumin market value in China, 2005-2009

Figure III-2.6 Lot release volume of imported human albumin, 2007-2009

Figure III-2.7 Forecast on human albumin output, 2010-2014

Figure III-2.8 Forecast on human albumin market value, 2010-2014

Figure III-3.1 Import and export situation of Chinese human vaccines, 2006-2009

Figure III-3.2 Vaccines import volume shares of import origins, 2009

Figure III-3.3 Market value of China's vaccine industry, 2006-2009

Figure III-3.4 Lot release volume of H1N1 Influenza A vaccine in China, 2009

Figure III-3.5 Forecast on China's H1N1 Influenza A vaccine output, 2010-2014

Figure III-3.6 Situation of domestic Inactivated Split Influenza vaccine lot release, 2007-2009

Figure III-3.7 Market capacity of Inactivated Split Influenza vaccine in China, 2007-2009

Figure III-3.8 Proportion of homemade and imported seasonal influenza vaccine in China, 2009

Figure III-3.9 Market share of seasonal influenza vaccine producers by volume in China, 2009

Figure III-3.10 Lot release volume of imported seasonal influenza vaccine in China, 2007-2009

Figure III-3.11 Forecast on China's influenza vaccine market capacity, 2010-2014

Figure III-3.12 Proportion of lot release volume of different HBV products, 2009

Figure III-3.13 China's HBV market capacity, 2007-2009

Figure III-3.14 Lot release volume of imported HBV in China, 2007-2009

Figure III-3.15 Forecast on HBV market capacity in China, 2010-2014

Figure III-4.2.1 Output value of RB industry and diagnostic reagents industry in China, 2005- 2009

Figure III-4.2.2 Share of different diagnostic reagents in China by output value, 2008

Figure III-4.4.1 Forecast on output value of diagnostic reagent in China, 2010-2015

Figure III-5.1.1.1 Output of four products in antibiotic industry in China, 2005-2009

Figure III-5.1.2.1 Major procedures of three steps fermentation technology for penicillin production

Figure III-5.1.3.1 Waste treatment procedure in Chinese antibiotic industry

Figure IV-1.1 Major procedure of diabetes treatment with stem cell

Figure IV-2.1 Major procedure of monoclonal antibody production

Figure IV-4.1 Major procedure of avian influenza vaccine production

Figure VIII-1.1.1 Chinese population and growth rate, 2000-2009

Figure VIII-1.1.2 Elderly population and its proportion, 2000-2009

Figure VIII-1.1.3 Per capital income and growth rate in urban areas

Figure VIII-1.1.4 Per capital income and growth rate in rural areas

Figure VIII-2.2.1 Exchange rate of CNY against USD

Figure VIII-2.2.2 Industrialization process of bio-pharmaceutical products

To order this report:

Biotechnology Industry: Future of Red Biotechnology in China

More  Market Research Report

Check our  Company Profile, SWOT and Revenue Analysis!

    
    
    Contact:
    Nicolas Bombourg
    Reportlinker
    Email: nbo@reportlinker.com
    US: (805)652-2626
    Intl: +1 805-652-2626


'/>"/>
SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved


Related biology technology :

1. Reportlinker Adds Infectious Disease Molecular Diagnostic Testing
2. Reportlinker Adds Smart Glass: Technologies and Global Markets Report
3. Reportlinker Adds Synthetic Biology: Emerging Global Markets Report
4. Reportlinker Adds Proteomics: Technologies and Global Markets Report
5. Reportlinker Adds Nanomedicine Report
6. Reportlinker Adds Small Molecule Kinase Inhibitors Report
7. Reportlinker Adds Nanoporous Materials Report
8. Reportlinker Adds Membrane Bioreactors Report
9. Reportlinker Adds The Future of Orphan Diseases Therapeutics - Market Forecasts to 2015, Pipeline Analysis and Reimbursement
10. Reportlinker Adds High-Tech Patient Monitoring Systems Markets (Remote and Wireless Systems, Data Processing, EMR Data Transfer) Report
11. Reportlinker Adds In Vitro Diagnostics in a Recession: IVD Market Forecasts, Analysis and Success Strategies Report
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... 2016  Alex,s Lemonade Stand Foundation (ALSF), a leading ... open a state-of-the-art bioinformatics lab, using ,big data, to ... comes as Liz Scott , co-executive director of ... Summit in Washington, D.C. , hosted ... and advocate of pediatric cancer research and awareness. ...
(Date:6/27/2016)... , June 27, 2016  Global demand for ... percent through 2020 to $7.2 billion.  This market ... beverages, cleaning products, biofuel production, animal feed, and ... diagnostics, and biocatalysts). Food and beverages will remain ... by increasing consumption of products containing enzymes in ...
(Date:6/27/2016)... , June 27, 2016 /PRNewswire/ - BIOREM Inc. (TSX-V: BRM) ... advised by its major shareholders, Clean Technology Fund I, ... United States based venture capital funds which ... Biorem (on a fully diluted, as converted basis), that ... of their entire equity holdings in Biorem to TUS ...
(Date:6/27/2016)...  Sequenom, Inc. (NASDAQ: SQNM ), a ... the development of innovative products and services, announced today ... States denied its petition to review decisions ... U.S. Patent No. 6,258,540 (",540 Patent") are not patent ... Supreme Court,s Mayo Collaborative Services v. Prometheus Laboratories decision.  ...
Breaking Biology Technology:
(Date:6/27/2016)... Research and Markets has announced the addition of the ... The report forecasts the biometrics ... a CAGR of 12.28% during the period 2016-2020. ... with inputs from industry experts. The report covers the market landscape ... includes a discussion of the key vendors operating in this market. ...
(Date:6/22/2016)... 2016  The American College of Medical Genetics and Genomics ... as one of the fastest-growing trade shows during the ... Bellagio in Las Vegas . ... growth in each of the following categories: net square feet ... of attendees. The 2015 ACMG Annual Meeting was ranked 23 ...
(Date:6/22/2016)... 22, 2016   Acuant , the ... solutions, has partnered with RightCrowd ® ... Visitor Management, Self-Service Kiosks and Continuous Workforce ... add functional enhancements to existing physical access ... venues with an automated ID verification and ...
Breaking Biology News(10 mins):